Viloxazine in the Treatment of Depressive Neurosis: A Placebo and Standard (Imipramine) Controlled Clinical Study

Abstract

In a 4-week double-blind trial, 33 patients with depressive neurosis were randomly assigned to either viloxazine, imipramine or placebo. Statistically significant improvement was observed in all treatment groups. Imipramine exhibited significant improvement earlier in depressive symptoms, while viloxazine showed significant improvement earlier in anxious symptoms. The same frequency of treatment emergent symptoms occurred in the treatment groups. Premature termination as a consequence of adverse reactions was required in only 1 viloxazine and 1 placebo patient.

Is viloxazine an antidepressant? A placebo‐controlled double‐blind study in major depressive disorder presenting in a general hospital

“…The small numbers may have contributed to the lack of statistical effects. The same group (Petrie et al, 1980) have reported a similar study using imipramine as the comparator. Once again no significant differences emerged between the three treatment groups on any of a wide range of well-validated outcome criteria.…”

A Collaborative Study of a New Antidepressant, Viloxazine, in Neurotic and Endogenous Depressives

“…As part of its program in psychopharmacology, the Tennessee Neuropsychiatrie Institute -Clini cal Research Services undertook a series of collaborative multicenter trials to investigate the efficacy and safety of the compound in heterogenous depressive populations. The results of two of these individual trials have been reported elsewhere [9,10].…”